FDA OKs Vutrisiran for hATTR Amyloidosis With Polyneuropathy FDA OKs Vutrisiran for hATTR Amyloidosis With Polyneuropathy

Vutrisiran, an RNAi therapeutic given by subcutaneous injection once every 3 months, significantly improved signs and symptoms of hATTR polyneuropathy in a phase 3 study.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Cardiology News Alert Source Type: news